
CareDx (CDNA) Stock Forecast & Price Target
CareDx (CDNA) Analyst Ratings
Bulls say
CareDx Inc. reported a strong +25% growth in revenue for Q4, driven by a +17% increase in volume and a +5% rise in average selling prices, alongside record revenue from patient and digital solutions. The company saw positive momentum in earlier quarters as well, with a +21% revenue increase in Q3 supported by similar trends in volume and average selling prices, culminating in the highest cash collections in its history in October. Furthermore, CareDx has raised its revenue estimates for 2026 and 2027, anticipating continued strong performance bolstered by an expanded sales force and high return on investment from ongoing business investments.
Bears say
CareDx Inc. faces a negative outlook primarily due to anticipated revenue impacts from the proposed LCD regulation, with a projected $7.5 million decrease in revenues reflected in its 2026 guidance, illustrating challenges in maintaining growth amid changing regulatory environments. Furthermore, while the company reported a year-over-year increase in testing volumes, the performance fell short of expectations, indicating potential weakness in demand and commercialization of additional diagnostic solutions critical to the company’s growth strategy. Lastly, CareDx's shares are trading at a significantly lower multiple compared to historical averages and peers in the diagnostics industry, with a low EBITDA margin run-rate of 16%, highlighting concerns regarding profitability and overall market confidence in the stock.
This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.
CareDx (CDNA) Analyst Forecast & Price Prediction
Start investing in CareDx (CDNA)
Order type
Buy in
Order amount
Est. shares
0 shares